Filing Details

Accession Number:
0001104659-22-129514
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-22 16:05:36
Reporting Period:
2022-12-22
Accepted Time:
2022-12-22 16:05:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1326190 Altimmune Inc. ALT Pharmaceutical Preparations (2834) 202726770
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1743611 Wayne Pisano C/O Altimmune, Inc., 910 Clopper Road
Suite 201S
Gaithersburg MD 20878
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Acquisiton 2022-12-22 20,000 $2.60 28,498 No 4 M Direct
Common Stock, Par Value $0.0001 Disposition 2022-12-22 20,000 $15.01 8,498 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, Par Value $0.0001 Stock Options (option to buy) Disposition 2022-12-22 20,000 $0.00 20,000 $2.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2029-01-02 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.0000 to $15.0900, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date.